254 related articles for article (PubMed ID: 26141397)
1. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis.
Kent DM; Dahabreh IJ; Ruthazer R; Furlan AJ; Weimar C; Serena J; Meier B; Mattle HP; Di Angelantonio E; Paciaroni M; Schuchlenz H; Homma S; Lutz JS; Thaler DE
Eur Heart J; 2015 Sep; 36(35):2381-9. PubMed ID: 26141397
[TBL] [Abstract][Full Text] [Related]
2. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack.
Li J; Liu J; Liu M; Zhang S; Hao Z; Zhang J; Zhang C
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009938. PubMed ID: 26346232
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis.
Angelini F; Fortuni F; Tsivgoulis G; Agnelli G; Bocchino PP; Franchin L; De Filippo O; Bellettini M; D'Ascenzo F; Crimi G; Leonardi S; De Ferrari GM; Paciaroni M
Cardiovasc Drugs Ther; 2021 Oct; 35(5):987-993. PubMed ID: 32918655
[TBL] [Abstract][Full Text] [Related]
4. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
[TBL] [Abstract][Full Text] [Related]
5. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
[TBL] [Abstract][Full Text] [Related]
6. close: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design.
Mas JL; Derumeaux G; Amarenco P; Arquizan C; Aubry P; Barthelet M; Bertrand B; Brochet E; Cabanes L; Donal E; Dubois-Randé JL; Durand-Zaleski I; Ernande L; Finet G; Fraisse A; Giroud M; Guérin P; Habib G; Juliard JM; Leys D; Lièvre M; Lusson JR; Marcon F; Michel P; Moulin T; Mounier-Vehier F; Pierard L; Piot C; Rey C; Rodier G; Roudaut R; Schleich JM; Teiger E; Turc G; Vuillier F; Weimar C; Woimant F; Chatellier G;
Int J Stroke; 2016 Aug; 11(6):724-32. PubMed ID: 27056964
[TBL] [Abstract][Full Text] [Related]
7. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
[TBL] [Abstract][Full Text] [Related]
8. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale.
Spencer FA; Lopes LC; Kennedy SA; Guyatt G
BMJ Open; 2014 Mar; 4(3):e004282. PubMed ID: 24607561
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of patent foramen ovale closure versus medical therapy for prevention of recurrent ischemic neurological events: Impact of medication type.
Pan X; Xu L; Zhou C; Zhang Z; Sun H
Medicine (Baltimore); 2021 Jun; 100(25):e26473. PubMed ID: 34160457
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale: Systematic Review and Meta-Analysis.
Sagris D; Georgiopoulos G; Perlepe K; Pateras K; Korompoki E; Makaritsis K; Vemmos K; Milionis H; Ntaios G
Stroke; 2019 Nov; 50(11):3135-3140. PubMed ID: 31547797
[TBL] [Abstract][Full Text] [Related]
12. Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials.
Vaduganathan M; Qamar A; Gupta A; Bajaj N; Golwala HB; Pandey A; Bhatt DL
Am J Med; 2018 May; 131(5):575-577. PubMed ID: 29229471
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events.
Pineda AM; Nascimento FO; Yang SC; Kirtane AJ; Sommer RJ; Beohar N
Catheter Cardiovasc Interv; 2013 Nov; 82(6):968-75. PubMed ID: 23832613
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials.
Pickett CA; Villines TC; Ferguson MA; Hulten EA
Tex Heart Inst J; 2014 Aug; 41(4):357-67. PubMed ID: 25120387
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Kasner SE; Swaminathan B; Lavados P; Sharma M; Muir K; Veltkamp R; Ameriso SF; Endres M; Lutsep H; Messé SR; Spence JD; Nedeltechev K; Perera K; Santo G; Olavarria V; Lindgren A; Bangdiwala S; Shoamanesh A; Berkowitz SD; Mundl H; Connolly SJ; Hart RG;
Lancet Neurol; 2018 Dec; 17(12):1053-1060. PubMed ID: 30274772
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
Saver JL; Carroll JD; Thaler DE; Smalling RW; MacDonald LA; Marks DS; Tirschwell DL;
N Engl J Med; 2017 Sep; 377(11):1022-1032. PubMed ID: 28902590
[TBL] [Abstract][Full Text] [Related]
17. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence.
Kitsios GD; Dahabreh IJ; Abu Dabrh AM; Thaler DE; Kent DM
Stroke; 2012 Feb; 43(2):422-31. PubMed ID: 22180252
[TBL] [Abstract][Full Text] [Related]
18. Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
Furlan AJ; Reisman M; Massaro J; Mauri L; Adams H; Albers GW; Felberg R; Herrmann H; Kar S; Landzberg M; Raizner A; Wechsler L;
N Engl J Med; 2012 Mar; 366(11):991-9. PubMed ID: 22417252
[TBL] [Abstract][Full Text] [Related]
19. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
20. Patent foramen ovale closure or medical therapy for secondary prevention of cryptogenic stroke: An update meta-analysis of randomized controlled trials.
Ma Y; Li D; Bai F; Qin F; Li J; Li Y; Liu N; Xie H; Zhou S; Liu Q
Medicine (Baltimore); 2018 Aug; 97(34):e11965. PubMed ID: 30142823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
